Liang Chen

Liang (Kevin) Chen has extensive work experience in the pharmaceutical and biotech industries. Liang (Kevin) is currently employed at CBC Group, where they hold the position of Vice President. Prior to this, they worked as an Assistant Vice President and Associate at the same company. In 2021, Liang co-founded Ensem Therapeutics and served as the Head of Strategy & Corporate Development. In 2019, they joined Everest Medicines, focusing on strategy development for oncology early clinical development. Before that, Liang held positions at Roche, Pfizer, and Johnson & Johnson, primarily in product management and medical specialist roles.

Liang (Kevin) Chen has a strong education history in various fields. Liang (Kevin) completed a Master's degree in Cancer Pharmacology & Toxicology through the Research Program at NYU Grossman School of Medicine. Liang (Kevin) also participated in the CSST Program at UCLA as a Research Scholar, focusing on Structural Biology. Additionally, they pursued a Certificate Program at the Massachusetts Institute of Technology in Machine Learning, Modeling, and Simulation: Engineering Problem-Solving in the Age of AI. Liang further expanded their knowledge as a Research Scholar at the Chinese Academy of Sciences, specializing in Computational Biochemistry for Drug Design. Liang (Kevin) obtained a Bachelor's degree in Bioengineering from Xi'an Jiaotong University, with a research focus on Hematology & Oncology.